Patients with impaired glucose tolerance or patients with diabetes
Conditions
Interventions
Oral administration of HYA (10-hydroxy-cis-12- octadecenoic acid)
Sponsors
Hirota Yushi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who are over 20 years and under 69 years at the time of consent acquisition (Regardless of gender) 2) Patients with BMI 25 kg/m 2 or more 3) Patients with impaired glucose tolerance and with diabetes mellitus 75 g OGTT diagnostic criteria for IGT or who do not use oral hypoglycemic drugs with HbA1c below 7.0%. 4) With regard to participation in this examination, patients who gained document consent by their own voluntary intention
Exclusion criteria
Exclusion criteria: 1) Patients with severe hepatic dysfunction 2) Patients with severe renal dysfunction 3) Patients with cancer 4) Patients who are treated with oral or intravenous steroids 5) Patients with the medical history of cardiovascular disease 6) Pregnant women or patients who may be pregnant or breast-feeding 7) Patients who have participated in other clinical trials related to weight loss or who have taken drugs or supplements that lead to weight loss in the last 3 months. 8) Patients who lose 5% of their weight within the last 3 months 9) Patients whom clinical researchers judged to be inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in HOMA-IR from before HYA administration to 12 weeks after administration | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Changes in HOMA-IR from before HYA administration to 4 or 8 weeks after administration 2. Changes in the 75g OGTT from before HYA administration to 12 weeks after administration 3. Changes in the body weight and abdominal circumference from before HYA administration to 4 or 8, 12 weeks after administration 4. Changes in the body composition from before HYA administration to 12 weeks after administration 5. Changes in the glucose metabolism marker from before HYA administration to 4 or 8, 12 weeks after administration 6. Changes in the pancreas glucagon and active GLP-1from before HYA administration to 12 weeks after administration 7. Changes in the adipokines from before HYA administration to 12 weeks after administration 8. Changes in the liver fibrosis marker from before HYA administration to 12 weeks after administration 9. Changes in the liver function from before HYA administration to 4 or 8, 12 weeks after administration 10. Changes in the lipid from before HYA administration to 12 weeks after administration 11. Changes in the free fatty acid from before HYA administration to 4 or 8, 12 weeks after administration 12. Changes in the short chain fatty acid concentration in stool from before HYA administration to 12 weeks after administration 13. Changes in the lipid metabolite in blood from before HYA administration to 12 weeks after administration (on target analysis) 14. Changes in the lipid metabolite in stool from before HYA administration to 12 weeks after administration (on target analysis) 15. Changes in the intestinal bacterial flora from before HYA administration to 12 weeks after administration 16. Whether or not adverse events after the start of HYA administration 17. Changes in the blood pressure from before HYA administration to 4 or 8, 12 weeks after administration | — |
Contacts
Public ContactYushi Hirota
Kobe University Hospital
Outcome results
None listed